Form 8-K · Current Report · Filed 2025-12-05
Natera Acquires Foresight Diagnostics for $450M
Natera, Inc. has acquired Foresight Diagnostics Inc., a cancer diagnostics company, in an all-stock transaction worth $450M. The acquisition, finalized on December 4, 2025, includes an upfront payment of $275M and $175M in earnouts contingent on revenue and reimbursement milestones. This strategic move aims to expand Natera's capabilities in molecular residual disease detection, particularly in B-cell lymphomas.
- Filer
- Natera Inc. NTRA · NASDAQ
- Filed
- Accession
- 0001104659-25-118664
- CIK
- 0001604821
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Unregistered Sales of Equity Securities
Other Events
Market reaction
Close before filing
$242.06
Next session
-1.2%
Since filing
+10.6%
Latest close
$267.76
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from NTRA reporting the same item, with the next session's move:
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Never miss another NTRA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.